Biomarker is a “biological indicator” used to measure onset and progression of a disease or as a marker of drug safety such as body temperature, blood pressure and heart rate. Imaging biomarkers (i-Biomarker) are used at Imanova to:
- Determine if the candidate drug reaches and engages the target
- Quantify the relationship between administered dose and target engagement
- Investigate the relationship between target and disease
- Demonstrate dose-dependent functional effects of candidate drug
- Define the ‘therapeutic window’ to optimise dose selection and minimise side effects
Imaging biomarkers have the advantage of being non-invasive and can be used for early detection of diseases, patient stratification, and provide an objective assessment for the response to treatment.
The main limiting factor for using molecular imaging studies for early stage drug development decision-making is the lack of available biomarkers. Imanova is an advocate of using imaging as an integral part of clinical research to help understand the basis of disease and in the support of the drug development process and has a dedicated i-Biomarker discovery and development service.
Imanova has developed and implemented 21 imaging biomarkers to Good Manufacturing Practice (GMP) standard since its inception. We have the capability and experience to help identify, evaluate, develop and implement biomarker candidates for use in both preclinical models and clinical (in humans) studies.
In addition to neurosciences, Imanova offers i-Biomarker development for other key therapeutic areas including oncology, inflammation, cardiology and respiratory diseases. For a complete list of all i-Biomarker available from Imanova, please click here.